Verified peer comparison

CVS vs JNJ

CVS Health Corporation compared with Johnson & Johnson. This page compares both source-verified company profiles and does not introduce an unverified price target.

CVS

CVS Health Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

CVS: Health Care Services

JNJ: Pharmaceuticals

Upside lens

CVS: Pricing, benefit redesign and membership actions can improve alignment between premiums and medical costs. Insurance, PBM, pharmacy and care-delivery assets can coordinate access and lower total care costs. Retail and specialty pharmacy scale can support purchasing economics and recurring prescription relationships.

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Risk lens

CVS: Higher utilization or acuity can outpace pricing and pressure insurance margins. Rebate, transparency and pharmacy-reimbursement reforms could alter Caremark economics. Leverage and complexity across acquired care assets can limit capital flexibility and delay returns.

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.